Journal: Cancer Immunology Research

Article Title: CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer

doi: 10.1158/2326-6066.CIR-22-0454

Figure Lengend Snippet: The phenotype and function of CD161 + CTLs. A, Heat map displaying expression values of discriminative genes between KLRB1 − and KLRB1 + CTLs (from clusters 0, 2, 3, and 9) based on the data from single-cell RNA sequencing. B, Scores for the terminal exhaustion signature, tissue-resident memory T-cell signature, and chemokine/IFNγ signature in KLRB1 − and KLRB1 + CTLs based on the data from single-cell RNA sequencing. C, Coexpression of cytotoxic cytokines and inhibitory receptors on CD161 − or CD161 + CTLs in OPSCC biopsies ( n = 13–19) via flow cytometry, paired Student t test. D, MFI of cytotoxic cytokines coexpressed on CD161 − or CD161 + CTLs treated with PD-1 or CD39 blocking antibodies in OPSCC biopsies ( n = 7–8), paired Student t test. E, MFI of IFNγ coexpressed on CD161 + CTLs treated with CD161-blocking antibodies for 72 hours in HPV + biopsies ( n = 3) and blood samples ( n = 4), paired Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. n.s.: no statistical significance.

Article Snippet: For the checkpoint blockade experiment, cryopreservated TILs or PBMCs were thawed, expanded, and seeded (5 × 10 5 cells/well) as described, and treated with PD-1 blocking monoclonal antibody (mAb; BioLegend, clone EH12.2H7, cat. #329926, 10 μg/mL), CD39 blocking mAb (Bio-Rad, clone A1, cat. #MCA1268EL, 10 μg/mL), or Tim-3 blocking mAb (BioLegend, clone F28-2E2, cat. #345004, 10 μg/mL) for 7 days.

Techniques: Expressing, RNA Sequencing, Flow Cytometry, Blocking Assay